Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22190340 | 0.89 | HDAC1 (0.69) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL10588753 | 0.85 | HDAC1 (0.70) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL14490981 | 0.84 | CCR5 (0.63) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL10027984 | 0.84 | HDAC1 (0.67) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL12507197 | 0.84 | POLB (0.59) | HDAC1 | |
| SCHEMBL20179119 | 0.82 | HDAC1 (0.68) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL1981652 | 0.82 | HDAC1 (0.69) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL8238392 | 0.82 | HDAC8 (0.89) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL2635132 | 0.80 | HDAC1 (0.67) | HDAC1HDAC2HDAC8HDAC6HDAC3 | |
| SCHEMBL13486138 | 0.80 | HDAC1 (0.67) | HDAC1HDAC2HDAC8HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859048-B2 | Selective placement of carbon nanotubes through functionalization | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2014-10-14 | — | — | US | disclosed |
| US-8283453-B2 | Selective placement of carbon nanotubes through functionalization | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-10-09 | — | — | US | disclosed |
| US-8138102-B2 | Method of placing a semiconducting nanostructure and semiconductor device including the semiconducting nanostructure | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-8084012-B2 | Selective placement of carbon nanotubes through functionalization | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110180777-A1 | METHOD OF PLACING A SEMICONDUCTING NANOSTRUCTURE AND SEMICONDUCTOR DEVICE INCLUDING THE SEMICONDUCTING NANOSTRUCTURE | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2011-07-28 | — | — | US | disclosed |
| US-20100145034-A1 | SELECTIVE PLACEMENT OF CARBON NANOTUBES THROUGH FUNCTIONALIZATION | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100044678-A1 | METHOD OF PLACING A SEMICONDUCTING NANOSTRUCTURE AND SEMICONDUCTOR DEVICE INCLUDING THE SEMICONDUCTING NANOSTRUCTURE | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090301349-A1 | SELECTIVE PLACEMENT OF CARBON NANOTUBES THROUGH FUNCTIONALIZATION | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080102213-A1 | Selective placement of carbon nanotubes through functionalization | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145034-A1 | SELECTIVE PLACEMENT OF CARBON NANOTUBES THROUGH FUNCTIONALIZATION | NOXO1, EPCAM, SCO2 | HDAC1 2966/4885HDAC2 3581/4885HDAC8 3238/4885 |
| US-20100041653-A1 | COMPOSITION AND METHODS FOR THE DESIGN AND DEVELOPMENT OF METALLO-ENZYME INHIBITORS | HELZ, MMEL1, GAA | HDAC1 28/4885HDAC2 150/4885HDAC8 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.